초록 ▼

This disclosure provides a newly developed strategy and particular options for differentiating pluripotent stem cells into cells of the hepatocyte lineage. Many of the protocols are based on a strategy in which the cells are first differentiated into early germ layer cells, then into hepatocyte prec

This disclosure provides a newly developed strategy and particular options for differentiating pluripotent stem cells into cells of the hepatocyte lineage. Many of the protocols are based on a strategy in which the cells are first differentiated into early germ layer cells, then into hepatocyte precursors, and then into mature cells. The cells obtained have morphological features and phenotypic markers characteristic of human adult hepatocytes. They also show evidence of cytochrome p450 enzyme activity, validating their utility for commercial applications such as drug screening, or use in the manufacture of medicaments and medical devices for clinical therapy.

대표청구항 ▼

The invention claimed is: 1. A process for differentiating primate pluripotent stem (pPS) cells into mature hepatocytes in at least three discrete steps, comprising: a) culturing undifferentiated pPS cells under conditions which cause differentiation of the cells into cells having characteristics o

The invention claimed is: 1. A process for differentiating primate pluripotent stem (pPS) cells into mature hepatocytes in at least three discrete steps, comprising: a) culturing undifferentiated pPS cells under conditions which cause differentiation of the cells into cells having characteristics of fetal endoderm; b) culturing the cells from a) under conditions which cause differentiation of fetal endoderm cells into cells having characteristics of hepatocyte progenitor cells; c) culturing the cells from b) under conditions which cause differentiation of hepatocyte progenitor cells into cells having characteristics of mature hepatocytes; thereby producing a cell population that has at least five of the following characteristics: antibody-detectable expression of α1-antitrypsin (AAT); antibody-detectable expression of albumin; absence of antibody-detectable expression of a-fetoprotein; RT-PCR detectable expression of asialoglycoprotein receptor (ASGR); evidence of glycogen storage; evidence of cytochrome p450 enzyme activity; evidence of glucose-6-phosphatase enzyme activity; and the morphological features of hepatocytes. 2. The process of claim 1, wherein the culturing in a) produces a cell population comprising cells expressing at least three markers selected from Hex, Sox17, HNF 3a, HNF 3b, and α fetoprotein (AFP). 3. The process of claim 1, wherein the culturing in b) produces a cell population comprising cells expressing at least three markers selected from γ-glutamyl tranpeptidase, HNF 4a isomer a7/a8, albumin, α1 antitrypsin (AAT), and Matripase 2. 4. The process of claim 1, wherein the culturing in c) produces a cell population comprising cells expressing at least three markers selected from ApoCII, tyrosine oxygenase (TO), CYP3A4 CYP3A7, HNF 4a isomer a1/a2, and LST 1. 5. The process of claim 1, wherein a) comprises culturing the cells with media comprising one of the following: DMSO, fibroblast growth factor 8 (FGF 8), or a bone morphogenic protein (BMP). 6. The process of claim 1, wherein b) comprises culturing the cells with media comprising one of the following: a histone deacetylase inhibitor, a BMP, epidermal growth factor (EGF), a corticosteroid, or Oncostatin M. 7. The process of claim 1, wherein c) comprises culturing the cells with media comprising one of the following: hepatocyte growth factor (HGF), or with one or more growth factors in combination with a histone deacetylase inhibitor. 8. The process of claim 1, comprising culturing the undifferentiated cells with DMSO, then with butyrate in the absence of growth factors, then with butyrate in combination with one or more growth factors. 9. The process of claim 1, comprising culturing the undifferentiated cells with DMSO, then with one or more growth factors in combination with Oncostatin M, optionally in the presence of a corticosteroid then with HGF. 10. The process of claim 1, comprising culturing the undifferentiated cells with a BMP, then with Oncostatin M, optionally in the presence of a BMP or a corticosteroid, then with HGF. 11. A process for differentiating human embryonic stem (hES) cells into hepatocyte lineage cells, comprising: a) culturing the undifferentiated pluripotent cells with DMSO, b) culturing the cells from a) with a histone deacetylase inhibitor in the absence of growth factors; and then c) culturing the cells from b) with a histone deacetylase inhibitor in combination with one or more growth factors thereby differentiating human embryonic stem (hES) cells into hepatocyte lineage cells. 12. The process of claim 11, wherein the histone deacetylase inhibitor is n butyrate. 13. The process of claim 1, wherein the pPS cells are obtained from a human blastocyst, or are the progeny of such cells. 14. The process of claim 1, wherein the pPS cells are human embryonic stem cells 15. A process for differentiating human embryonic stem (hES) cells into hepatocyte lineage cells, comprising: a) culturing undifferentiated hES cells with DMSO; b) culturing the cells from a) with one or more growth factors in combination with Oncostatin M; and then c) culturing the cells from b) with hepatocyte growth factor (HGF) thereby differentiating human embryonic stem (hES) cells into heQatocyte lineage cells. 16. The process of claim 15, wherein a) further comprises culturing the cells with FGF 1, FGF 2, FGF4 or FGF 8. 17. The process of claim 15, wherein b) comprises culturing the cells with EGF or FGF in combination with Oncostatin M and dexamethasone. 18. A process for differentiating human embryonic stem (hES) cells into hepatocyte lineage cells, comprising: a) culturing undifferentiated hES cells with FGF 8 or a bone morphogenic protein (BMP); b) culturing the cells from a) with Oncostatin M, and then c) culturing the cells from b) with HGF thereby differentiating human embryonic stem (hES) cells into hepatocyte lineage cells. 19. The process of claim 18, wherein a) comprises culturing the cells with at least two bone morphogenic proteins selected from BMP 2, BMP 4, and BMP 7, optionally in the presence of dexamethasone. 20. The process of claim 18, wherein b) comprises culturing the cells with a BMP, dexamethasone, or nerve growth factor (NGF).